|
Patent landscape, scope, and claims summary: |
United States Patent 10,059,765: Claims, Strength, and Competitive Patent Landscape
What does US 10,059,765 claim at a technical level?
US 10,059,765 claims combination immunotherapy for humans that pairs:
- A “therapeutic” antibody (or antigen-binding fragment) that binds a target-cell antigen but not NK cells, with:
- ADCC capability via binding to CD16 through the antibody Fc (Fc region to CD16), and
- the target antigen being expressed on “target cells” that drive the disease (tumor, virus-infected, pathological cell types, etc. per dependent claims).
- An “NK cell-potentiating” antibody (or antigen-binding fragment) that binds an NK inhibitory receptor and blocks it (claim set 1-21), or that stimulates an NK activating receptor (claim 22-23), in an amount sufficient to enhance ADCC-mediated depletion of the therapeutic antibody’s target cells.
Core claim architecture
- Independent claim (1): therapeutic CD16-engaging ADCC antibody + anti-inhibitory NK receptor blocker that potentiates ADCC.
- Dependent claims (2-21): specify antibody class/Fc, receptor families and epitopes, and quantitative enhancement thresholds.
- Alternative independent claim (22): therapeutic CD16-engaging ADCC antibody + anti-activating NK receptor stimulator.
- Dependent claim (23): specifies activating receptor examples (NKp30, NKp44, NKp46, NKG2C, NKG2E, NKG2D, KIR2DS44).
Claim-critical constraints (what must be true for infringement)
The claims are not satisfied by a generic “ADCC antibody plus immune modulator” approach. They require tight functional-and-binding relationships:
- Therapeutic antibody binding pattern
- Antibody binds an antigen expressed on target cells but not on NK cells.
- CD16 engagement
- The therapeutic antibody binds via its Fc region to CD16.
- It mediates depletion by ADCC.
- NK potentiator mechanism
- In claim set 1-21: the NK potentiator binds and blocks an inhibitory receptor expressed on NK cell surface.
- In claim set 22-23: the NK potentiator stimulates activating receptors.
- Potentiation linkage
- The NK potentiator is present in an amount sufficient to enhance efficacy by enhancing ADCC depletion by the therapeutic antibody.
- Disease nexus
- The disease is mediated at least in part by target cells expressing the therapeutic antibody antigen.
These constraints create high entry barriers for design-around only if competitors keep both the therapeutic antibody and the NK-modulating component outside the specified functional frame.
What exactly are the dependent claims trying to lock down?
Antibody format and Fc constraints
- Claim 2: therapeutic antibody Fc portion is human or non-human primate IgG1 or IgG3.
- Claim 6: therapeutic antibody is not conjugated with a radioactive or toxic moiety.
- Claim 7: therapeutic antibody can be rituximab or alemtuzumab.
Landscape impact: these do not limit the entire independent claim to rituximab/alemtuzumab, but they create a clear center of gravity around standard IgG1/IgG3 ADCC formats and named marketed exemplars.
NK inhibitory receptor scope (broad family list plus specific embodiments)
- Claim 8: NK inhibitory receptor is one of:
- KIR2DL1, KIR2DL2/3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, LILRBS.
- Claim 9: focus on KIR2DL1 or KIR2DL2/3.
- Claim 20: expands selectable inhibitory receptor list to:
- KIR2DL1, KIR2DL2/3, KIR2DLSA, KIR2DLSB, KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, LILRBS.
Functional epitope/competition binding lock
The patent pushes beyond receptor category into competitive/epitope-level restrictions:
- Claim 10: anti-inhibitory antibody can (examples)
- inhibit KIR2DL-mediated inhibition,
- inhibit KIR2DL1 and KIR2DL2/3-mediated inhibition, or
- inhibit binding of HLA-C variants at position 80 to KIR2DL receptors:
- HLA-C Lys80 to KIR2DL1, and
- HLA-C Asn80 to KIR2DL2/3.
- Claim 11: anti-inhibitory antibody binds an epitope “as does” specific deposited monoclonals:
- DE200 (hybridoma DF200; deposited CNCM 1-3224) and/or EB6.
- Includes “binds the same epitope”, “competes for binding”, or “comprises” DF200/EB6 or fragments/derivatives.
Landscape impact: claim 11 is an explicit effort to anchor scope to specific antibodies (DE200 and EB6) via deposit identifiers, which can constrain later equivalents and raise proof burden for challengers arguing lack of enablement or non-infringement.
Quantitative potentiation thresholds
- Claim 13: enhancement of depletion by therapeutic antibody by:
- at least 30% or at least 50%.
- Claim 14: therapeutic antibody has essentially no ADCC in absence of anti-NK blocker.
- Claim 21: enhancement of depletion by ADCC by:
- at least 100%, at least 200%, or at least 300%.
Landscape impact: these thresholds are powerful for enforcement because they convert mechanism into measurable performance. They also create factual questions around assay design and potency comparators, which can become litigation friction if competitors seek to argue “not enough enhancement” or different baseline ADCC.
Target antigen list is expansive
- Claim 15 provides a long list of antigens, including:
- CD20, CD52, CD33, HLA-DR, CD22, HER2/ERBB2, CA125, MUC1, EpCAM, VEGFR/VEGFR2, VLA-4 integrin, ICAM-3, IL-8, TRAIL-R1, BlyS, Lewis Y, VE-cadherin, CD56, mesothelin, PS: MSA, CD19/CD3, and many others.
Landscape impact: this listing is meant to prevent “antigen argument” defenses. It also suggests the patent is written to cover many mainstream oncology targets and some immune antigens.
What does claim set 22-23 add?
Independent claim 22 shifts the NK potentiator type:
- therapeutic CD16-Fc ADCC antibody + NK cell-potentiating antibody that binds and stimulates an activating receptor (instead of blocking inhibitory receptors).
Claim 23 defines examples:
- NKp30, NKp44, NKp46,
- NKG2C, NKG2E, NKG2D,
- KIR2DS44.
Landscape impact: this is a second axis of coverage. Even if a competitor designs around KIR/LILR inhibitory blockade, the patent can still reach NK activation strategies, though only within the activating receptor list.
How strong are these claims, critically?
Claim strength positives
-
Mechanism is tightly coupled to CD16 ADCC
- The “Fc region binds CD16” and “capable of ADCC-mediated depletion” requirements narrow prior art that uses ADCC without explicit CD16 engagement, or uses Fc-effector pathways not aligned with CD16 binding.
-
NK potentiation is functional and quantitative
- Enhancement thresholds and “essentially no ADCC in absence” (claim 14) strengthen argumentability that the combination produces a synergistic effect rather than additive immune modulation.
-
Specific inhibitory receptor families and epitope anchors
- The patent targets KIR2DL/KIR3DL and LILR receptors plus receptor/HLA-C interaction logic.
- Claim 11’s anchor to deposited DE200/EB6 increases enforceability against close variants.
-
Large therapeutic antigen coverage
- Claim 15’s antigen list reduces the ability to avoid infringement by selecting a different but adjacent antigen.
Claim strength vulnerabilities (how competitors attack)
-
Breadth on therapeutic antibody format vs. mechanism constraint
- While the patent lists IgG1/IgG3 for claim 2, claim 1 itself is not limited to IgG1/IgG3. Competitors can sometimes position on:
- different Fc-engineering that alters CD16 binding characteristics, or
- engineered constructs lacking the “binds via its Fc region to CD16” condition.
-
“Not on NK cells” limitation is a biological condition
- The claim requires target-cell antigen is expressed on target cells but not on NK cells. For some shared antigens (immune markers), competitors can argue expression overlap at the relevant NK population, which can become a factual and expert-evidence dispute.
-
“Essentially no ADCC” baseline is assay-dependent
- Claim 14 creates enforceable power if the baseline is clean. It also creates litigation complexity if assay definitions differ (effector:target ratios, NK donor variability, Fc receptor genotypes, and readout thresholds).
-
Epitope/competition claims require exact proof
- Claim 11 improves scope control but can limit enforcement if competitors use different epitopes and can show non-competition.
-
Activating receptor pathway is narrower
- Claim 22-23 is receptor-list constrained. If competitors choose other activating receptors or use bispecifics that do not map cleanly to the listed receptors, they may avoid claim 23.
Where does this sit in the NK checkpoint landscape?
US 10,059,765 is structurally aligned with a broad strategy: release NK inhibition (or force activation) to amplify ADCC from clinically established monoclonal antibodies.
The claims expressly cover:
- Inhibitory checkpoints primarily from:
- KIR2DL/KIR3DL and
- LILR families,
- and a second mode covering activating receptors (NKp30/44/46; NKG2C/E/D; KIR2DS44).
In practice, this landscape overlaps with:
- KIR2DL blockade approaches, and
- NK activation receptor agonism approaches,
but the patent distinguishes itself by embedding the NK modulator inside a specific ADCC-potentiation framework tied to CD16-Fc engagement and quantitative enhancement.
How to read infringement risk by program type (practical decision framework)
Higher infringement risk (claim 1-21)
Programs that combine:
- an ADCC-capable CD16-binding IgG1/IgG3 therapeutic antibody (or equivalent fragments), whose antigen is not on NK cells,
with
- an anti-KIR2DL/KIR3DL/LILR inhibitory receptor antibody blocking NK inhibitory signaling,
and show that the inhibitory blocker is required to obtain substantial ADCC depletion.
Most exposed regions of scope:
- KIR2DL1/KIR2DL2/3 focus (claims 8-10, 19),
- “binds same epitope/competes with DE200 or EB6” (claim 11),
- performance thresholds (claims 13, 14, 21).
Moderate infringement risk (claim 22-23)
Programs that combine:
- a CD16-engaging ADCC antibody
with
- activating receptor agonist antibodies targeting only the named receptors.
Risk reduces if the agonist targets receptors outside NKp30/44/46, NKG2C/E/D, and KIR2DS44, or if it uses non-antibody modalities that do not satisfy “antibody or antigen-binding fragment thereof” language.
Lower infringement risk / likely design-around
- therapeutic antibody engineered to weaken or eliminate CD16 binding through Fc, or using Fc designs that do not satisfy “binds via its Fc region to CD16.”
- NK potentiators targeting inhibitory receptors outside the enumerated KIR2DL/KIR3DL/LILR groups or not blocking the inhibitory receptor as claimed.
- NK potentiators whose mechanistic effect is not framed as enhancing “depletion by ADCC” in a way that meets “at least X%” thresholds.
Competitive patent landscape: what other filings likely collide?
A comprehensive assessment requires the full prosecution history, claim construction, and bibliographic data. That information is not included in the input. With only the claim text, the only defensible conclusion is structural: the patent claims a combination framework that could overlap with other NK checkpoint ADCC combination approaches, but a definitive “who owns what” mapping cannot be produced without the patent family data and cited references for US 10,059,765.
Practical “landscape map” of scope boundaries (from the claims only)
| Boundary in US 10,059,765 |
What it captures |
Design-around lever |
| Therapeutic antibody binds target antigen “not on NK cells” |
NK depletion driven by target expression |
Use antigens with NK expression overlap at relevant NK subsets |
| Fc binds CD16; ADCC depletion |
Standard ADCC biology |
Use Fc formats that do not bind CD16 as required |
| NK potentiator blocks inhibitory receptors |
KIR2DL/KIR3DL/LILR inhibition blockade |
Block different receptor class or not inhibitory blockade |
| Epitope anchors to DE200 (CNCM 1-3224) / EB6 |
Specific anti-KIR antibody families |
Use non-competing epitopes and show lack of competition |
| Quant thresholds (30/50/100/200/300%) |
Potentiation magnitude |
Target combination that does not reach thresholds in comparable assays |
| Optional “essentially no ADCC” baseline |
Synergy logic |
Demonstrate therapeutic antibody has baseline ADCC without potentiator |
| Alternative activation mode (claim 22-23) |
Named activating receptors only |
Choose other activating receptors or modalities |
Key Takeaways
- US 10,059,765 is an ADCC-potentiation patent: it requires a CD16-binding, ADCC-capable therapeutic antibody plus an NK checkpoint antibody that either blocks inhibitory receptors (KIR2DL/KIR3DL/LILR enumerated) or stimulates activating receptors (NKp30/44/46, NKG2C/E/D, KIR2DS44).
- Scope is function-locked and measurable via enhancement thresholds (30%, 50%, 100%-300%) and an “essentially no ADCC without potentiator” limitation.
- Enforceability is strengthened by:
- explicit inhibitory receptor lists,
- HLA-C/KIR2DL logic,
- and an epitope/competition lock to DE200 (CNCM 1-3224) and EB6 in claim 11.
- Primary design-around vectors are:
- eliminating the required CD16 Fc binding condition,
- selecting NK targets outside the enumerated receptor sets,
- and positioning the combination performance below the claimed enhancement thresholds or failing the baseline ADCC premise.
FAQs
1) Does US 10,059,765 cover any ADCC antibody plus any NK modulator?
No. The therapeutic antibody must bind a target-cell antigen that is not expressed on NK cells, must bind CD16 via its Fc, and must mediate depletion by ADCC. The NK modulator must either block enumerated inhibitory receptors (claim 1-21) or stimulate enumerated activating receptors (claim 22-23).
2) Are there explicit receptor names and lists in the claims?
Yes. For inhibitory receptors, the claims list KIR2DL/KIR3DL and LILR family members (including KIR2DL1 and KIR2DL2/3 prominently). For activation receptors, claim 23 lists NKp30, NKp44, NKp46, NKG2C, NKG2E, NKG2D, and KIR2DS44.
3) How do the claims treat synergy?
They do it in measurable terms. Claims include enhancement thresholds (30%/50% and 100%-300%) and a baseline condition that the therapeutic antibody elicits essentially no ADCC absent the NK inhibitor (claim 14).
4) What is the role of DE200 and EB6 in the claim set?
Claim 11 ties scope to antibodies that bind the same epitope as DE200 (DF200, CNCM 1-3224) or EB6, including competitive binding and “comprises” formulations of DF200/EB6 or fragments/derivatives.
5) Does the patent restrict radionuclide or toxin conjugates?
Yes for claim 6. It states the therapeutic antibody or antigen-binding fragment is not conjugated with a radioactive or toxic moiety.
References
[1] United States Patent 10,059,765 (claim text provided in prompt).
More… ↓
⤷ Start Trial
|
